Methods for predicting ancestral viral sequences and uses thereof

Ancestral viral sequences and particles, predicted through advanced bioinformatics methods, address the issue of pre-existing immunity in gene transfer vectors by reducing seroprevalence and immune neutralization, improving the efficiency and safety of gene transfer and vaccination.

JP7595731B2Active Publication Date: 2024-12-06MASSACHUSETTS EYE & EAR INFARY +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023188537
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2013-10-11
Filing Date
2023-11-02
Publication Date
2024-12-06
Estimated Expiration
2034-10-10

AI Technical Summary

Technical Problem

Existing gene transfer methods using virus-based vectors face challenges due to pre-existing immunity in humans, leading to reduced efficiency and safety risks, particularly with adenoviruses and adeno-associated viruses (AAV), as they trigger immune responses and are seroprevalent in the population.

Method used

The development of ancestral viral sequences and particles, specifically for AAV, which are predicted to have lower seroprevalence and immune recognition, allowing for reduced neutralization by human serum, using methods such as multiple sequence alignment and phylogenetic analysis to synthesize ancestral capsid polypeptides and nucleic acids.

Benefits of technology

Ancestral viral sequences and particles demonstrate significantly lower seroprevalence and immune neutralization, enhancing the efficiency and safety of gene transfer and vaccination by minimizing immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595731000029
    Figure 0007595731000029
  • Figure 0007595731000030
    Figure 0007595731000030
  • Figure 0007595731000031
    Figure 0007595731000031
Patent Text Reader

Abstract

To provide methods for predicting and synthesizing ancestral viral sequences or portions thereof, and virus particles containing such ancestral viral sequences.SOLUTION: The present disclosure provides a gene transfer method, a method of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides, a method for predicting and synthesizing ancestral viral sequences or portions thereof, and the reduced seroprevalance exhibited by virus particles containing ancestral sequences relative to virus particles containing contemporary sequences.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to viruses. [Background technology]

[0002] Evading neutralizing or toxic immune responses to gene therapy vectors is essential for all This is a major issue when using gene transfer vectors. Vectors based on viruses that circulate in humans and animals, such as adenoviruses and adenoviruses. This is most efficiently achieved using adeno-associated viruses (AAV). If elephants are naturally infected with a virus, the possibility exists that subsequent infections with vectors based on that virus could be The treatment of HIV-1 infection is associated with increased safety risks and reduced gene transfer efficiency due to cellular and humoral immune responses. The capsid antigen is mainly responsible for the innate immunity and / or immunity against the virus particle. or adaptive immunity, but the polypeptides encoded by the viral genes Peptides can also be immunogenic. Summary of the Invention [Means for solving the problem]

[0003] The present disclosure describes methods for predicting and synthesizing ancestral viral sequences or portions thereof, and further We describe viral particles that contain such ancestral viral sequences. The methods described herein have been applied to adeno-associated viruses (AAV); thus, the present disclosure provides Ancestral AAV sequences and AAV viral particles containing such ancestral AAV sequences The present disclosure also describes a virus particle that is similar to that of the present invention, but contains a more specific sequence. The present study describes the reduced seroprevalence exhibited by virus particles containing ancestral sequences compared to the seroprevalence exhibited by virus particles containing ancestral sequences. do.

[0004] In one embodiment, the present disclosure relates to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15 and 1 7, an adeno-associated virus (AAV) capsid having an amino acid sequence selected from the group consisting of AAV capsid polypeptides, e.g., synthetic and / or artificial AAV capsid polypeptides. In some implementations, the AAV capsid polypeptide or the AAV capsid The viral particle containing the polypeptide may be an AAV2 capsid polypeptide or an AAV2 capsid polypeptide. AAV capsids have a lower seroprevalence than viral particles containing capsid polypeptides. The viral particle containing the polypeptide or the AAV capsid polypeptide is an AAV8 capsid. AAV8 capsid polypeptide or a virus particle containing the AAV8 capsid polypeptide. In some embodiments, the AAV capsid fragment exhibits the same or a lower seroprevalence. The viral particles containing the AAV2 capsid polypeptide or the AAV capsid polypeptide are less than 100% of viral particles containing the AAV2 capsid polypeptide or the AAV2 capsid polypeptide. Neutralized by human serum at 100% and does not bind to AAV capsid polypeptides or AAV capsids The viral particle containing the polypeptide may be an AAV8 capsid polypeptide or an AAV8 capsid polypeptide. Capsid polypeptide-containing viral particles are reacted with human serum to a similar or lesser extent. In some embodiments, the AAV capsid polypeptide is purified and neutralized. The AAV capsid polypeptides provided herein are represented by SEQ ID NOs: 2, 4, , 6, 8, 10, 12, 14, 16 and 18. It can be coded as follows.

[0005] In one embodiment, the present disclosure provides SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16 and An adeno-associated virus (AAV) capsid having a nucleic acid sequence selected from the group consisting of 18. The present invention provides nucleic acid molecules, e.g., synthetic and / or artificial nucleic acid molecules, that encode polypeptides. Also provided are vectors containing such nucleic acids and host cells containing such vectors. The cells are provided.

[0006] In another aspect, the disclosure provides an AAV capsid polypeptide as described herein. In some embodiments, the viral particles are Contains a transgene.

[0007] In other embodiments, the present disclosure provides SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25 and and 26, and Adeno-associated virus (AAV) capsids with sequence identity of at least 8, 99 or 100% and / or artificial AAV capsid polypeptides. In some embodiments, the AAV capsid polypeptide or the AAV capsid polypeptide is The viral particle containing the AAV2 capsid polypeptide is referred to as the AAV2 capsid polypeptide or AAAV2 capsid polypeptide. The AAV capsid has a lower seroprevalence than virions containing the V2 capsid polypeptide. AAV capsid polypeptide or a viral particle containing an AAV capsid polypeptide is an AAV 8 capsid polypeptide or a viral particle containing an AAV8 capsid polypeptide In some embodiments, the AAV capsids exhibit similar or lower seroprevalence. A viral particle containing the capsid polypeptide or the AAV capsid polypeptide is called AAV2. From a viral particle containing a capsid polypeptide or an AAV2 capsid polypeptide Neutralized to a low extent by human serum, and AAV capsid polypeptide or AAV capsid The viral particle containing the AAV8 capsid polypeptide is referred to as the AAV8 capsid polypeptide or AAAV8 capsid polypeptide. V8 capsid polypeptide-containing virus particles are expressed in human serum to a similar or lesser extent. In some embodiments, the AAV capsid polypeptide is purified. It is manufactured.

[0008] In another embodiment, the AAV capsid polypeptide described herein is In one implementation, the present disclosure provides an adenovirus vector that can be encoded by a nucleic acid sequence described in A nucleic acid molecule encoding an AAV capsid polypeptide is provided, wherein In some embodiments, the nucleic acid molecule has at least 95% (e.g., 97, 98, 99 or 100%) of sequence identity. The present disclosure also includes such nucleic acid molecules. A vector is provided and a host cell contains such a vector.

[0009] In one aspect, the disclosure provides a method for the preparation of at least one AAV capsid polypeptide as described herein. In some embodiments, the viral particle comprises at least one The offspring contain the transgene.

[0010] In certain embodiments, the present disclosure provides a method for administering to a subject in need of gene transfer or vaccination: Methods of administering the viral particles described herein are provided. In some embodiments, In some cases, viral particles show a lower seroprevalence than AAV2 viral particles. In embodiments, the viral particles have about the same or lower serum concentration as AAV8 viral particles. In some embodiments, the viral particles are more highly virulent than AAV2 viral particles. AAV virus particles are neutralized by human serum to a lesser extent than AAV8 virus particles. is neutralized by human serum to a similar or lesser extent.

[0011] In one aspect, the present disclosure provides a method for administering to a subject in need of vaccination a vaccine as described herein. Methods for administering a target antigen operably linked to an AAV capsid polypeptide are provided. In some embodiments, the AAV capsid polypeptide is an AAV2 capsid. In some embodiments, the AAV capsid exhibits a lower seroprevalence than the AAV polypeptide. The capsid polypeptide has a serum prevalence similar to or lower than that of the AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptide is an AAV2 capsid polypeptide. AAV capsid polypeptide is neutralized by human serum to a lesser extent than AAV capsid polypeptide. The peptides were found to be as or less abundant in human serum than the AAV8 capsid polypeptide. Thus, it is neutralized.

[0012] In another aspect, the present disclosure provides an in silico method for predicting the sequence of an ancestral virus or a portion thereof. Such methods typically involve the detection of multiple contemporary viruses or preparing a nucleotide or amino acid sequence derived from a portion of the Aligning sequences using the Multiple Sequence Alignment (MSA) algorithm; modeling evolution and multiple Obtaining a predicted ancestral phylogeny of contemporary viruses or parts thereof; At each position in the sequence, a specific nucleotide or estimating the evolutionary probabilities of amino acid residues; and based on the estimated probabilities at each position This involves predicting the sequence of an ancestral virus or a part of it based on the sequence of the ancestral virus.

[0013] In some embodiments, one or more or all of the steps are computer implemented. In some embodiments, the MSA algorithm is implemented using a system processor. Phylogenetic information can be used to determine whether gaps in the alignment are the result of deletions or insertions. In some embodiments, the MSA algorithm predicts whether a In some embodiments, the evolution modeling kit is The model used to match the variances was selected using the Aikake Information Criterion (AIC). In some embodiments, the predicted ancestral phylogeny is calculated using a gamma distribution model ("+ It is obtained using the JTT model with the frequency calculation of πi ("+F"). In an embodiment, the modeling of the evolutionary steps is performed using the JTT+G+F model. In some embodiments, the method further comprises identifying an ancestral virus or a variant thereof based on the predicted sequence. In some embodiments, the method includes synthesizing the ancestral virus or a portion thereof. The method includes assembling the vector or a portion thereof into an ancestral virus particle.

[0014] In some embodiments, the method also provides a method for determining whether a gene is capable of (a) replicating; (b) introgressing; (c) receptor binding; or (d) seroprevalence. In some embodiments, the ancestral virus particles include A virus particle assembled from at least one of several contemporary viruses or a part thereof In some embodiments, the ancestral viral particles exhibit a lower seroprevalence than the offspring. A virus particle assembled from at least one contemporary virus or part thereof In some embodiments, multiple simultaneous The viruses or parts thereof include adenoviruses (AV), human immunodeficiency viruses (HI), V), retrovirus, lentivirus, herpes simplex virus (HSV), vaccinia Viruses, poxviruses, influenza viruses, respiratory syncytial viruses, parasites belonging to a family selected from the group consisting of influenza viruses and foamy viruses. do.

[0015] Thus, the present disclosure provides a method for identifying and determining the presence of virions in modern human populations, as compared to contemporary viruses or subsets. The present invention provides an ancestral virus or a part thereof that exhibits reduced susceptibility to pre-existing immunity in a mammalian animal. Generally, the pre-existing immunity displayed by ancestral viruses or parts of them in the current human population Reduced susceptibility to infection is reflected as reduced susceptibility to neutralizing antibodies.

[0016] Unless otherwise defined, all technical and scientific terms used herein are intended to The term "method and composition" means the same as commonly understood by those of ordinary skill in the art to which the method and composition pertains. Methods and materials similar or equivalent to those described herein are of interest. Suitable methods and materials can be used in practicing or testing the compositions and methods described below. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, and other materials mentioned herein are the property of their respective owners. References are incorporated by reference in their entirety.

[0017] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication, including any drawings, will be provided upon request and upon payment of the required fee. Provided by the Patent Office upon payment. [Brief description of the drawings]

[0018] [Figure 1] Figure 1 is a schematic showing the relationship between ancestral / contemporary viral infections and ancestral / contemporary host immune responses. [Diagram 2] Figures 2A to 2D are a series of schematic diagrams illustrating an example of the ancestral reconstruction procedure. Data shown are excerpted from the full dataset and represent residues 564 to 584 (AAV2-VP1 numbering). [Diagram 3] Figures 3A to 3C together show a phylogenetic tree of AAV contemporary sequences produced using the methods described herein. [Figure 4] Figures 4A and 4B together show an alignment of the ancestral AAV VP1 polypeptide. [Figure 5A] Figures 5A and 5B together show an alignment of functional ancestral and contemporary AAV VP1 polypeptides. [Figure 5B] Figures 5A and 5B together show an alignment of functional ancestral and contemporary AAV VP1 polypeptides. [Figure 6] FIG. 6 is an electrophoretic gel demonstrating that the ancestral AAV VP1 sequence is transcribed and alternatively spliced ​​similarly to the contemporary AAV VP1 sequence. [Figure 7] FIG. 7 is a graph showing luciferase activity in HEK293 cells transduced with ancestral AAV vectors. [Figure 8] FIG. 8 is a graph demonstrating that ancestral AAV vectors were more resistant to IVIG neutralization than contemporary AAV vectors. [Figure 9] FIG. 9 is a graph showing sequence comparison between the Anc80 library and Anc80L65 (above the diagonal is % and below is the number of aa differences). [Figure 10] Figure 10A-D are images of experimental results demonstrating that Anc80L65 can assemble and produce high titer particles. Panel A shows that Anc80L65 can produce vector yields comparable to AAV2; Panel B is a TEM image of virus particles containing Anc80L65; Panel C shows that virus particles containing Anc80L65 can produce AAV cap VP1, 2 and 3 proteins based on SDS-PAGE gel under denaturing conditions; Panel D shows a Western blot of Anc80L65 using AAV capsid antibody, B1. [Figure 11] 11A-C are images of experimental results demonstrating that Anc80L65 can infect cells in vitro on HEK293 cells using GFP as a readout (panel A) or luciferase (panel B) versus AAV2 and / or AAV8 control, and further efficiently targets to the liver after IV injection of AAV encoding a nuclear LacZ transgene (top row, panel C: liver), after direct IM injection of AAV encoding GFP (middle row, panel C: muscle), and after subretinal injection with AAV encoding GFP (bottom row, panel C: retina). [Figure 12] Figures 12A-D are graphs demonstrating that Anc80L64 is minimally seropositive in sera from a human population (panel A) or a Belgian population (panel B), a Boston population (panel C) or a cynomolgus monkey (panel D) using IVIg. [Figure 13A]Figures 13A and 13B are sequence identity matrices generated using MAFFT showing the amino acid sequence of the VP1 protein of an ancestral vector aligned with the amino acid sequence of a representative extant AAV (Figure 13A), and the amino acid sequence of the VP3 protein of an ancestral vector aligned with the amino acid sequence of a representative extant AAV (Figure 13B). [Figure 13B] Figures 13A and 13B are sequence identity matrices generated using MAFFT showing the amino acid sequence of the VP1 protein of an ancestral vector aligned with the amino acid sequence of a representative extant AAV (Figure 13A), and the amino acid sequence of the VP3 protein of an ancestral vector aligned with the amino acid sequence of a representative extant AAV (Figure 13B). [Figure 14] Figure 14 is a graph demonstrating that AAV vectors were produced in triplicate at small scale (6-well dishes). Crude virus was assessed by quantitative PCR to determine absolute production of each vector. [Figure 15] FIG. 15 is a table showing the titers of each vector averaged and compared to the titer of AAV8. [Figure 16] Figure 16 is a photograph showing the results of an experiment in which 1.9E3 GC / cell of each vector was added to HEK293 cells (except for Anc126, in which case an MOI of 2.5E2-3.1E2 GC / cell was achieved). After 60 hours, infectivity was assessed using a fluorescent microscope. [Figure 17] Figure 17 is a graph showing the results of an experiment in which the same cells as in Figure 16 were lysed and assayed for luciferase expression. As in Figure 16, Anc126 was not titer controlled with the other vectors, but rather at an MOI range of 2.5E2-3.1E2 GS / cell. [Figure 18] FIG. 18 is a table showing the luminescence of cells transduced with each vector, averaged and compared to the luminescence of AAV8. [Figure 19] FIG. 19 is a chart providing an overview of the in vitro experiments to determine the relative production and infectivity of the ancestral AAV vectors described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Gene transfer for experimental or therapeutic purposes involves shuttling genetic information into target cells. The vector or vector system is It is believed to be a major determinant of the efficiency, specificity, host response, pharmacology, and life span of gene transfer reactions. Currently, the most efficient and effective method to achieve gene transfer is replication-deficient Through the use of virus-based vectors or vector systems that have been be.

[0020] However, seroprevalence studies suggest that a significant proportion of the global human population is currently infected with have been previously exposed (e.g., by natural infection) to the majority of viruses used in child transfer , thus indicating pre-exposed immunity. Neutralizing antibodies against viral vectors can sometimes significantly limit the extent of gene transfer. It is known that they can induce or redirect viruses away from their targets. For example, Calcified o et al. (2009, J. Infect. Dis., 199:381-90), and Boutin et al. (2010, Huma See, e.g., J. Med. Soc., 21:704-12. Thus, the present disclosure relates to ancestral viruses or that some of these viruses are more prevalent in modern human populations than contemporary viruses or parts of them. Recognition that the subject exhibits reduced susceptibility to immunity (e.g., reduced susceptibility to neutralizing antibodies) Based on.

[0021] Figure 1 shows the relationship between ancestral and contemporary viral infections and ancestral and contemporary host immune responses. Figure 1 shows a schematic diagram of how ancestral AAVs overcome the preexisting immune responses of the contemporary Contemporary, extant viruses (Vc) show that they may be responsive to immune evasion mechanisms. It is suggested that the genus Vanc evolved mainly under the evolutionary pressure of host immunity through the These species Vanc and Vc are involved in the regulation of B-cell and T-cell immunity, respectively. They have the ability to induce adaptive immunity, including Ianc and Ic, respectively. The immunity induced by this virus may be substantially different in epitope composition than current viruses. It is assumed that the virus does not necessarily cross-react with a potential ancestral virus species, and as used herein Confirmed.

[0022] The present disclosure provides a method for predicting the sequence of an ancestral virus or a portion thereof. One or more of the predicted ancestral viral sequences are generated using the methods described, As demonstrated herein, the predicted ancestral nuclei can be assembled into particles. Virus particles assembled from proviral sequences are more likely to be assembled from modern, contemporary virus particles. The seroprevalence of the virus may be much lower, and sometimes significantly lower. The ancestral viral sequences that are present in the vectors or vector systems for gene transfer It is suitable for use in

[0023] Methods for predicting and synthesizing ancestral viral sequences To predict the ancestral viral sequence, the nucleotide or amino acid sequence is first cloned. The method described herein is carried out by collecting adenoviruses from a number of contemporary viruses or parts thereof. Although exemplified using AAV capsid sequences, the same method can be used with AAV-derived capsid sequences. It may be applied to other sequences (e.g., whole genome, rep sequences, ITR sequences), or any other The present invention can be applied to any virus or part thereof. Viruses other than AAV include, but are not limited to, However, adenoviruses (AV), human immunodeficiency viruses (HIV), retroviruses, Antivirus, Herpes simplex virus (HSV), measles, vaccinia virus, poxvirus Viruses, influenza virus, respiratory syncytial virus, parainfluenza virus Viruses such as sarcoma, foamy viruses, or any other virus for which pre-existing immunity is thought to be an issue Examples include:

[0024] Sequences from as few as two contemporary viruses or parts of them can be used. However, the majority of sequences of contemporary viruses or parts of them are available from as many current sources as possible. It is desirable to include a picture of the sequence diversity of the It is understood that this is to increase the predictive ability of the algorithm being used. For example, 0 or more contemporary viruses or their parts can be used, and 50 or more Sequences derived from the above contemporary viruses or parts thereof can be used, or 100 Sequences derived from these contemporary viruses or parts thereof can be used.

[0025] Such sequences can be found, for example, but not limited to, GenBank, UniProt, EM BL, International Nucleotide Sequence Database Collaboration (INSDC) or European Nucleotide Sequence Database Collaboration (EBSD) The information may be obtained from any number of public databases, including the National Archives of Or alternatively, such sequences can be found in databases specific to particular organisms (e.g., The contemporary sequences can correspond to the entire genome, Or only a portion of the genome, for example, but not limited to, the viral capsid, replication proteins, Sequences encoding one or more components of the protein or ITR sequences can be used. do.

[0026] The contemporary sequences were then aligned using a multiple sequence alignment (MSA) algorithm. Figure 2(a) is a schematic diagram showing multiple sequence alignment. Algorithms are well known in the art and generally correspond to different sizes of data sets and different applied to the input (e.g., nucleic acid or protein) and a particular method (e.g., dynamic processing) It is designed to align sequences by a number of methods (programming, progressive, heuristic). , different scoring schemes in alignments (e.g., matrix-based or or consistency-based, e.g., min-entropy, sum of pairs, similarity matrix, gap A well-known MSA algorithm is, for example, ClustalW. (Thompson et al., 1994, Nuc. Acids Res., 22:4673-90), Kalign(Lassmann e t al., 2006, Nuc. Acids Res., 34:W596-99), MAFFT (Katoh et al., 2005, Nuc. Acids Res., 33:511-8), MUSCLE (Edgar, 2004, BMC Bioinform., 5:113) and and T-Coffee (Notredame et al., 2000, J. Mol. Biol., 302:205-17). can be.

[0027] As described herein, MS One of the main features to consider when choosing an A algorithm is that the algorithm A method for handling gaps. Gaps in sequence alignments are handled by dividing the gap size by In this method, a penalty value can be assigned that is dependent or independent of The MSA algorithm used in the method described herein is based on the gap bias. In contrast to non-phylogenetic processing, which was performed using , to predict whether gaps in an alignment are the result of deletions or insertions. It is preferable to apply phylogenetic information. Appropriate methods and evolutionary analyses are described in Loytynoja and Goldman, 2008, Science, 320:1632-5. and aligning gaps in a manner suitable for use in the methods described herein. A commercially available algorithm that applies the algorithm is Probabilistic Alignment Kit (PRANK; Goldman Sachs, 2011). n Group Software; Loytynoja and Goldman, 2005, PNAS USA, 102:10557-62), A variation of the PRANK algorithm.

[0028] An evolutionary model is then applied to the resulting alignment to obtain a predicted ancestral phylogeny. (See FIG. 2(b)). There are many evolutionary models available in the art. There are three variants, each of which applies a slightly different matrix of substitution rates for amino acids. Algorithms for applying evolutionary models include, but are not limited to, Dayhoff Models (e.g., PAM120, PAM160, PAM250; Dayhoff et al., 1978, In Atlas of Protein Sequence and Structure (ed. Dayhoff), pp. 345-52, National B iOmedical Research Foundation, Washington DC), JTT model (Jones et al., 19 92, Comp. Appl. Biosci., 8:275-82), the WAG model (Whelan and Goldman, 2001, Mol . Biol. Evol., 18:691-9), and Blosum models (e.g., Blosum45, Blosum62, Blosum80;Henikoff and Henikoff, 1992, PNAS USA, 89:10 915-9).

[0029] Moreover, the constraints that structure and function impose on evolutionary models are themselves likely to be inappropriate, e.g. Irregularity ("+I"; Reeves, 1992, J. Mol. Evol., 35:17-31), in some positions undergo different rates of change ("+G"; Yang, 1993, Mol. Biol. Evol., 10:1396- 1401), and / or the balanced frequency of nucleotides or amino acids is the same as the alignment. ("+F"; Cao et al., 1994, J. Mol. Evol., 39:519-27) and

[0030] The fitness of one or more models of evolution is evaluated using the Akaike Information Criterion (AIC; Akaike, 1973, In Second International Symposium on Information Theory, Petrov and Csaki, eds., pp 267-81, Budapest, Akademiai Kiado), Bayesian Information Criterion (BIC; Schwarz, 1978 , Ann. Statist. 6:461-4), or any variation or combination thereof. In addition, AIC, BIC, or variations or combinations thereof can be used. The fitting involves adjusting one or more parameters in the evolutionary model (e.g., the constraints discussed above). ) can be used to assess the relative importance of including

[0031] As described in the Examples section below, ProTest3 (Darriba et al., 2011, Bibliography) was used. oinformatics, 27(8):1164-5) based on the minimum AIC, the JTT+G+F algorithm was the most suitable model for AAV evolution. The JTT+G+F algorithm can also identify ancestral polypeptides other than the AAV capsid polypeptide. It will be appreciated by those skilled in the art that the present invention may be used to predict viral sequences. However, depending on the dataset and the fitness score, different models of evolution may be better. It will be appreciated by those skilled in the art that other suitable methods may be suitable.

[0032] Once an evolutionary model has been selected and its fitness determined, the viral sequence or a part of it is Phylogenetic trees can be constructed. Constructing phylogenetic trees is known in the art. Typically, a maximum likelihood method is used, e.g., PhyML (Guindon and Gascuel, 200 3, Systematic Biology, 52:696-704)), MOLPHY (Adachi and Hasegawa, 1996, e d. Tokyo Institute of Statistical Mathematics), BioNJ (Gascuel, 1997, Mol. Biol. Evol., 14:685-95), or PHYLIP (Felsenstein, 1973, Systematic Bio Those skilled in the art will appreciate that computer calculations can be performed using the A balance between complexity and the beneficial portion of fitness is desirable in models of amino acid substitution. You will understand.

[0033] If desired, the phylogenetic tree can be evaluated for significance. A number of statistical methods are available to are available and routinely used to assess the significance of data, including but not limited to: Rootstrap, jackknife, cross-validation, permutation validation or a combination of these The significance can also be measured using, for example, the approximate likelihood ratio test (aLR T; Anisimova and Gascuel, 2006, Systematic Biology, 55:539-52) obtain.

[0034] At any phylogenetic node of the phylogeny (e.g., an internal phylogenetic node), the sequence by estimating the evolutionary probability of a particular nucleotide or amino acid residue at each position in the sequence. The phylogenetic nodes can be reconstructed by the predicted ancestral As used herein, "evolutionary probability" refers to the probability of evolution occurring at an intermediate evolutionary branch point in a phylogenetic tree. In contrast to models that do not take into account evolutionary shifts, such as those in codon usage, It refers to the probability that a particular nucleotide or amino acid is present at a particular position based on the An exemplary model that considers the evolution probability of a particular nucleotide or amino acid residue at position For example, but not limited to, phylogenetic analysis by maximum likelihood method (PAML; Yang, 1999). 97, Comp. Applic. BioSci., 13:555-6) or phylogenetic analysis using parsimony methods (PA UP; Sinauer Assoc., Inc., Sunderland, MA). It may be approximated using any number of maximum likelihood methods.

[0035] Based on the estimated evolutionary probability of a particular nucleotide or amino acid residue at each position The predicted sequences of the ancestral viruses or parts thereof are assembled and either completely or partially Synthetic nucleic acid or polypeptide sequences can be formed. If desired, any residue can be It is possible to calculate the likelihood of being in a given state at a given node along the nodes, and the likelihood is calculated below a certain threshold. Any position along the sequence with the calculated posterior probability can be identified (Figure 2(d) ). In this way, we can include variations at those positions that have a probability below a certain threshold. It is possible to generate ancestral scaffold sequences that may be used to identify the target gene.

[0036] When the ancestral sequence predicted using the methods described herein is a nucleic acid sequence, the sequence may be The codons may be optimized so that they can be efficiently translated into amino acid sequences. Codon usage tables are known in the art. The usage table is based on homology (e.g., at least 90% sequence identity) to the ancestral scaffold sequence. The present invention can be designed based on one or more contemporary sequences having the The ancestral sequence is codon optimized for mammalian (e.g., human) codon usage. could be.

[0037] Any or all of the methods outlined herein for predicting ancestral viral sequences. The steps may be implemented using a processor or a microprocessor-based computer (e.g., It can be implemented or simulated in silico.

[0038] Ancestral adeno-associated virus (AAV) scaffold sequences The methods described herein are directed to the development of contemporary chimeric antigen receptors (described in detail in the Examples below). The capsid sequence was used to develop adeno-associated viruses (AAVs). AAVs are used to develop therapeutic genes. Possible gene transfer vectors and genetic vaccine vehicles, but in human populations Using the methods described herein, phylogenetic trees were generated that show high seroprevalence of contemporary AAV The sequences were assembled (see Figures 3A-3C) and the predicted ancestral scaffold sequences were As used herein, the ancestral scaffold sequence is a sequence derived from the phylogenetic node of the ancestral scaffold (Table 1). , using the methods described herein (e.g., using evolvability and evolutionary modeling) As used herein, "antibody" refers to a sequence that has been constructed and is not known to exist in nature. When performing a sequence matching, the ancestral scaffold sequence typically includes a nucleotide or amino acid residue at a particular position. It is different from the consensus sequence constructed using the base frequencies.

[0039] [Table 1]

[0040] The scaffold sequence of the Anc80 polypeptide is shown in SEQ ID NO:1, which is shown in SEQ ID NO:2. The scaffold sequence of Anc80 is encoded by the scaffold sequence of the Anc80 nucleic acid. The scaffold sequence of Anc80 consists of two residues Either of the residues contains the predicted 11th position. Thus, the Anc80 scaffold sequence is 48(2 11 ) different sequences.

[0041] The effectiveness of the methods described herein for predicting the ancestral sequence of a virus or a portion thereof To demonstrate the relevance of the sequence, we compared the alignment of 2048 predicted ancestral sequences in AAV Anc80. A library is prepared and cloned with contemporary capsid polypeptides as described herein. Low seroprevalence, in some cases significantly lower, compared with assembled virus particles It has been demonstrated that it forms viable virus particles that demonstrate seroprevalence.

[0042] Methods for producing ancestral virus particles After obtaining the predicted ancestral sequence of the virus or part thereof, the actual nucleic acid molecule and / or Alternatively, the polypeptide(s) can be produced, e.g., synthetically produced. For example, artificial nucleic acid molecules or polypeptides can be generated based on sequences obtained in silico. Methods for this purpose are known in the art and include, for example, chemical synthesis or recombinant cloning. Further methods for producing a nucleic acid molecule or a polypeptide are known in the art. These techniques are well known and are discussed in more detail below.

[0043] Once the ancestral polypeptide is generated, or the ancestral nucleic acid molecule is generated, the ancestral polypeptide When expressed to produce The components of the virus particle (e.g., The rep sequence, cap sequence, and inverted terminal repeat (ITR) sequence are each independently selected from the group consisting of Transiently or stably transfected into packaging host cells using one or more vectors One or more of the components of the viral particle can be any of the components described herein. based on predicted ancestral sequences, while the remaining components are based on contemporary sequences In some instances, the entire virus particle can be generated based on the predicted ancestral sequence. It can be done.

[0044] Such ancestral virus particles can be purified using conventional methods. As used herein, a "purified" virus particle refers to a component in a mixture in which it is produced, e.g. For example, but not limited to, viral components (e.g., rep sequence, cap sequence), package from aging host cells and partially or incompletely assembled virus particles. It means the viral component that is removed.

[0045] Once assembled, ancestral virus particles possess e.g., the ability to replicate; gene transfer properties; receptor binding capacity; and / or seroprevalence in a population (e.g., a human population). The determination of whether a viral particle is capable of replicating is well known in the art. This is typically done by infecting a host cell with a certain amount of virus particles, This involves determining whether viral particles increase in number over time. Determining whether gene transfer can be performed is routine in the art and typically involves The transgene (e.g., a detectable gene such as a reporter gene, which is discussed in more detail below) is expressed in the The method includes infecting a host cell with a viral particle containing a gene (such as a transgene). Following infection and clearance, host cells are assessed for the presence or absence of the transgene. Determining whether a viral particle binds to its receptor is routine in the art. Such methods can be performed in vitro or in vivo.

[0046] Determining the seroprevalence of viral particles is routinely performed in the art and typically involves the determination of the seroprevalence of viral particles in an individual. determining the prevalence of one or more antibodies in a sample (e.g., a blood sample) from a particular population of Seroprevalence includes the use of immunoassays to identify individuals who are seropositive (i.e. It is commonly understood to mean the proportion of subjects in a population that are exposed to a particular pathogen or immunogen. As understood in the art, a particular It is calculated as the number of subjects in a population who produce antibodies against a pathogen or immunogen. Immunoassays are well known in the art and include, but are not limited to, immunoblots, immunoassays, and the like. Western blot, enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA) A) or radioimmunoassay (RIA). Protovirus particles are not contemporaneous viral particles (i.e., contemporaneous viral sequences or As just one example, Xu et al. (2007, Am. J. Obstet. Gynecol., 196:43.e1-6); Paul et al. (19 94, J. Infect. Dis., 169:801-6);Sauerbrei et al. (2011, Eurosurv., 16(44):3) ; and Sakhria et al. (2013, PLoS Negl. Trop. Dis., 7:e2429). Each determined the seroprevalence for a particular antibody in a given population.

[0047] As described herein, ancestral viral particles are capable of infecting the human immune system, e.g., the immune system of a patient. The virus is neutralized by the virion strain to a lesser extent than contemporary virus particles. Several methods are available for determining the degree of neutralization. Sei is the antibody that neutralizes infection by 50% or more compared to a control sample that does not contain any antibody. The titer containing the total concentration of the antibody was measured. 2) and Manning et al. (1998, Human Gene Ther., 9:477-85).

[0048] For the ancestral AAV capsid polypeptides exemplified herein, seroprevalence And / or the degree of neutralization can be determined by, for example, the expression of an AAV8 capsid polypeptide or an AAV 8. A virus particle comprising a capsid polypeptide, or an AAV2 capsid polypeptide or compared to a viral particle containing the AAV2 capsid polypeptide. In general, AAV8 capsid polypeptides or viral particles are considered to have low viral load. showed seroprevalence and resulting neutralization in the AAV2 capsid population, while The virion polypeptide or virus particle has a serum prevalence in the human population that is considered to be high. It is understood in the art that the expression of a specific agonist, which is indicative of pathology and consequent neutralization, is a potent inhibitor of the agonist. The seroprevalence of AAV8 depends on the population studied and the immunological method used, but is approximately 22% to a maximum of approximately 38%, whereas AAV2 showed a seroprevalence of approximately 43.5% to a maximum of approximately The seroprevalence of IgG is 72%. See, for example, Boutin et al. 2010, “Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8 and 9 in the healthy po pulation: implications for gene therapy using AAV vectors,” Hum. Gene Ther., 21 See also Calcebo et al. 2009, J. Infect. Dis., 199:381-90. Please refer to.

[0049] Predicted adeno-associated virus (AAV) ancestral nucleic acid and polypeptide sequences from a library encoding a predicted ancestral capsid polypeptide of section Anc80 A number of different clones were sequenced and the predicted capsid polypeptides of representative AAVs were identified. The amino acid sequences of the peptides are SEQ ID NO: 19 (Anc80L27); SEQ ID NO: 20 (Anc80L 59); SEQ ID NO:21 (Anc80L60); SEQ ID NO:22 (Anc80L62); SEQ ID NO: SEQ ID NO:23 (Anc80L65); SEQ ID NO:24 (Anc80L33); SEQ ID NO:25 (A and SEQ ID NO: 26 (Anc80L44). It will be appreciated that the nucleic acid sequence encoding this amino acid sequence can be readily determined.

[0050] having the sequence shown in SEQ ID NO: 19, 20, 21, 22, 23, 24, 25 or 26 In addition to the predicted ancestral capsid polypeptides shown in SEQ ID NOs: 19, 20, 21, 22, The predicted ancestral capsid polypeptide having the sequence shown in 23, 24, 25 or 26 At least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity Also provided are nucleic acid molecules encoding the ancestral capsid polypeptides and at least At least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%) %, at least 99% or 100% sequence identity) (i.e., at least 9 5% sequence identity) are provided.

[0051] In calculating percent sequence identity, two sequences are aligned and the nucleotide sequence identity between the two sequences is calculated. The number of identical matches of nucleotides or amino acid residues is determined. The number of identical matches is calculated based on the number of identical matches in the aligned regions. divided by the length of the region (i.e., the number of aligned nucleotides or amino acid residues) , multiplied by 100 to arrive at a percent sequence identity value. It is understood that the may be a portion of one or both sequences up to the full length size of the shortest sequence. Also, a single sequence can be aligned with more than one other sequence, thus , each of which may have a different percent sequence identity value for the aligned region. It is understood that it is possible.

[0052] Alignment of two or more sequences to determine percent sequence identity is performed using the World BLAST (Basic Local Attributes) available on the Web at ncbi.nlm.nih.gov The results of the Altschul et al. (1997, Nu This can be done using the algorithm described by E. Cleic Acids Res., 25:3389-3402. BLAST searches are performed using sequences aligned using the algorithm of Altschul et al. The percent sequence identity between (nucleic acid or amino acid) and any other sequence or portion thereof BLASTN can be used to align nucleic acid sequences and determine the sequence identity between nucleic acid sequences. BLASTP is a program used to compare amino acid identity. A program used to align sequences and compare identity between amino acid sequences. Use the BLAST program to calculate the percent identity between a sequence and another sequence. When doing so, the default parameters of each program are generally used.

[0053] Representative alignments are shown in Figures 4A and 4B and Figures 5A and 5B. Alignment of the ancestral AAV VP1 capsid polypeptides, showing Anc80L65 (SEQ ID NO: 23), Anc80L27 (SEQ ID NO: 19), Anc80L33 (SEQ ID NO: 2 4), Anc80L36 (SEQ ID NO: 25), Anc80L44 (SEQ ID NO: 26), Anc 80L59 (SEQ ID NO: 20), Anc80L60 (SEQ ID NO: 21) and Anc80L6 2 (SEQ ID NO: 22). The alignment shown in Figures 4A and 4B identifies 11 sites , which are predicted variations in each of the sequences and may be artifacts of cloning. , confirming one non-synonymous mutation at position 609E of Anc80L60 (SEQ ID NO: 21) 5A and 5B show the structure of the ancestral AAV VP1 capsid polypeptide (Anc80L65 (SEQ ID NO: 1)). Row number 23), Anc80L27 (SEQ ID NO: 19), Anc80L33 (SEQ ID NO: 24) , Anc80L36 (SEQ ID NO: 25), Anc80L60 (SEQ ID NO: 21), Anc80 L62 (SEQ ID NO: 22), Anc80L44 (SEQ ID NO: 26) and Anc80L59 (SEQ ID NO: 20)) and the contemporary AAV VP1 capsid polypeptide (AAV8 (SEQ ID NO: SEQ ID NO: 27), AAV9 (SEQ ID NO: 28), AAV6 (SEQ ID NO: 29), AAV1 (SEQ ID NO: No. 30), AAV2 (SEQ ID NO: 31), AAV3 (SEQ ID NO: 32), AAV3B (SEQ ID NO: 5A and 5B show the alignment between AAV7 (SEQ ID NO: 33) and AAV7 (SEQ ID NO: 34). The alignments in the present study showed that the ancestral AAV sequence was approximately 85%–91% similar to the contemporary AAV sequences. It indicates that the sequence has the same sequence identity as the above.

[0054] Also provided is a vector containing a nucleic acid molecule encoding the polypeptide. Vectors containing the target can be commercially available or produced by recombinant techniques. A vector containing a molecule is a vector that contains a nucleic acid molecule operably linked to the molecule for expression. It may also have one or more elements encoding a selectable marker. Nucleic acid molecules (e.g., antibiotic resistance genes) and / or polypeptides (e.g., 6 The nucleic acid molecule may be used for purification of the nucleic acid sequence (e.g., a nucleic acid tag (xHis tag)). Expression elements include nucleic acid sequences that direct and control the expression of a nucleic acid coding sequence. An example of an expression element is a promoter sequence. an inducible gene that regulates the expression of a nucleic acid molecule, such as a promoter, enhancer sequence, response element, or nucleic acid molecule; The expression elements may include bacterial, yeast, insect, mammalian or Vectors may be of viral origin and may contain a combination of expression elements from different sources. As used herein, operably linked means capable of being linked to a nucleic acid sequence for expression. The elements of the coding sequence are directed to or regulate the expression of the coding sequence. It is meant to be placed in a vector relative to the sequence.

[0055] Nucleic acid molecules, e.g., nucleic acid molecules in vectors (e.g., expression vectors, viral vectors) The nucleic acid molecule may be introduced into a host cell. The term "host cell" refers to the particular It refers not only to the cell or cells, but also to the progeny or potential progeny of such cells. A number of suitable host cells are known to those of skill in the art; host cells include prokaryotic cells. (e.g., E. coli) or eukaryotic cells (e.g., yeast cells, insect cells, plant cells Representative host cells include, but are not limited to, human, hamster, and mammalian cells. A549, WE, and other mammalian origins, including mice, rats, rabbits, and hamsters. HI, 3T3, 10T1 / 2, BHK, MDCK, COS1, COS7, BSC1, BS C40, BMT10, VERO, WI38, HeLa, 293 cells, Saos, C2C1 2, L cells, HT1080, HepG2, as well as primary fibroblasts, hepatocytes and myoblasts Methods for introducing nucleic acid molecules into host cells are known in the art, including These include, but are not limited to, calcium phosphate precipitation, electroporation, heat shock, lipofuscin, and the like. Injection, microinjection and viral-mediated nucleic acid transfer (e.g., transduction ) are included.

[0056] With respect to a polypeptide, "purified" means free from cellular components which naturally accompany it. It means an isolated or purified polypeptide (i.e., a peptide or polypeptide). Typically, the polypeptide comprises at least 70% (e.g., at least 7 "Purified" means that the product is 5%, 80%, 85%, 90%, 95% or 99% pure. It does not include naturally occurring molecules that are naturally associated with polypeptides. The polypeptide to be produced is essentially separated from components which naturally accompany it, and therefore Although synthetic polypeptides are considered "purified," in addition, the polypeptides may be synthesized using The components (e.g., amino acid residues) used for the synthesis of nucleic acid molecules can be removed. In the context of "isolated," "isolated" refers to a nucleic acid molecule that is separated from other nucleic acid molecules with which it is normally associated in the genome. Additionally, an isolated nucleic acid molecule refers to a nucleic acid molecule that is recombinant or synthetic. The nucleic acid molecule may include a genetically engineered nucleic acid molecule such as a nucleic acid fragment.

[0057] Polypeptides may be purified by DEAE ion exchange, gel filtration and / or hydroxyapatite. The protein may be extracted from a natural source (e.g., a biological sample) by known methods such as chromatography. The purified polypeptide can also be obtained (e.g., purified) by, for example, expressing the polypeptide in an expression vector. The polypeptide can be obtained by expressing a nucleic acid molecule or by chemical synthesis. The degree of purity of the peptide can be determined by any suitable method, for example, column chromatography, polyacrylamide gel electrophoresis, or the like. This can be measured using acrylamide gel electrophoresis or HPLC analysis. Nucleic acid molecules can be prepared by conventional methods, including but not limited to recombinant nucleic acid techniques (e.g., recombinant nucleic acid synthesis). restriction enzyme digestion and ligation) or polymerase chain reaction (PCR; e.g. Primer: A Laboratory Manual, Dieffenbach & Dveksler, Eds., Cold Spring Harbor La The isolated polypeptide can be obtained (e.g., isolated) using a method such as the use of a cloning agent (see, for example, US Pat. No. 6,313,316, published in the Journal of Clinical Chemistry, 1995). The nucleic acid molecule can be chemically synthesized.

[0058] Methods using ancestral viruses or parts of them The ancestral viruses or parts thereof described herein, in particular contemporaneous viruses or parts thereof Some of the studies that show reduced seroprevalence compared to others have been used in numerous research and / or therapeutic applications. For example, the ancestral viruses described herein or their derivatives can be used in Some are used in human or veterinary medicine for gene therapy (e.g. vectors for gene transfer). in a target or vector system) or for vaccination (e.g. for antigen presentation) More specifically, the ancestral viruses or Some of these include gene addition, gene augmentation, gene delivery of polypeptide preparations, and gene vaccines. inoculation, gene silencing, genome editing, gene therapy, RNAi delivery, cDNA delivery , mRNA delivery, miRNA delivery, miRNA sponging, genetic immunity, optogenetic gene May be used for gene therapy, gene recombination, DNA vaccination or DNA immunization can.

[0059] Host cells can be grown in vitro (e.g., during growth in culture) or in vivo (e.g., The subject may be transduced or infected with an ancestral virus or a part thereof. Host cells that can be transduced or infected in vitro with ancestral viruses or parts thereof are disclosed herein. transduced or infected in vivo with an ancestral virus or a portion thereof; Host cells that may be cultured include, but are not limited to, cells from the brain, liver, muscle, lung, eye (e.g., retina, retina, omentum, etc.) membrane pigment epithelium), kidney, heart, gonads (e.g., testes, uterus, ovaries), skin, nasal cavity, digestive tract system, pancreas, pancreatic islet cells, nerve cells, lymphocytes, ear (e.g., inner ear), hair follicles and / or glands (e.g., thyroid gland).

[0060] The ancestral viruses or portions thereof described herein may be expressed in cis or transgenic (with other viral sequences) or in vivo. The transgene can be modified to contain a transgene, e.g. For example, reporter genes (e.g., β-lactamase, β-galactosidase (LacZ) , alkaline phosphatase, thymidine kinase, green fluorescent polypeptide (GFP), lambphenicol acetyltransferase (CAT) or luciferase, is a fusion polypeptide containing an antigen tag domain, such as hemagglutinin or Myc) or Therapeutic genes (e.g., hormones or their receptors, growth factors or their receptors, activating factors or their receptors, immune system regulators (e.g., cytokines and interleukins) or its receptor, enzyme, RNA (e.g., inhibitory or catalytic RNA) or can be a gene encoding a target antigen (eg, a carcinogenic antigen, an autoimmune antigen).

[0061] The particular transgene will depend, at least in part, on the particular disease or deficiency being treated. By way of example only, gene transfer or gene therapy can be used to treat hemophilia, retinitis pigmentosa, cysts, fibrosis, Leber's congenital amaurosis, lysosomal storage disorders, inborn errors of metabolism (e.g., ferric leukemia, Congenital anomalies of amino acid metabolism such as phenylketonuria, and organic acid metabolism such as propionic acidemia Congenital anomalies, congenital anomalies of fatty acid metabolism such as medium-chain acyl-CoA dehydrogenase deficiency (MCAD) cancer, color vision disorders, cone-rod dystrophy, macular degeneration (e.g. age-related macular degeneration) ), lipopolypeptide lipase deficiency, familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscular dystrophy, Alzheimer's disease, Parkinson's disease, obesity, inflammatory Intestinal disease, diabetes, congestive heart failure, hypercholesterolemia, hearing loss, coronary heart disease, Familial renal amyloidosis, Marfan syndrome, fatal familial insomnia, Creutzfeldt syndrome Cobb's disease, sickle cell disease, Huntington's disease, frontotemporal lobar degeneration, Usher syndrome, lactose intolerance Tolerance, lipid storage disorders (e.g., Niemann-Pick disease, type C), Batten disease, congenital choroidal defect Type II glycogen storage disease (Pompe disease), ataxia telangiectasia (Louiver syndrome), congenital Hypothyroidism, severe combined immunodeficiency (SCID) and / or amyotrophic lateral sclerosis ( It can be applied to the treatment of ALS.

[0062] The transgene may also be administered to a subject (e.g., a human, an animal (e.g., a companion animal, a domestic animal, For example, the immunogen may be an immunogen that is useful for immunization of an organism (such as a livestock or an endangered animal). For example, a pathogenic organism) or an immunogenic portion or component thereof (for example, a toxin polypeptide As an example, an immunogenic polypeptide can be obtained from the Pathogenic organisms from which the virus can be obtained include viruses (e.g., picornaviruses, enteroviruses, viruses, orthomyxoviruses, reoviruses, retroviruses), prokaryotes (e.g. , Pneumococci, Staphylococci, Listeria , Pseudomonas) and eukaryotic organisms (e.g., amebiasis, malaria , leishmaniasis, nematodes). The compositions produced by the methods are not limited by any particular transgene. It is understood that this is not the case.

[0063] Typically, ancestral viruses or parts thereof suspended in a physiologically compatible carrier are targeted (e.g. The pharmaceutical composition may be administered to a mammal, such as a human or a non-human mammal. Suitable carriers include a variety of saline, which may be formulated using a suitable buffer solution (e.g., phosphate buffered saline); Lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin and The ancestral virus or a part of it can transduce or infect cells and cause excessive To obtain sufficient levels of gene transfer and expression to provide therapeutic benefit without the side effects of The conventional and pharmacologic routes of administration include For example, but not limited to, direct delivery to an organ such as the liver or lungs, oral, intranasal, or inhaled for intraductal, inhalation, intravenous, intramuscular, intraocular, subcutaneous, intradermal, mucosal, or other routes of administration. If desired, routes of administration can be combined.

[0064] The dose of ancestral virus or a portion thereof administered to a subject will primarily affect the condition being treated, if any. The dosage will depend on factors such as the age, weight, and health of the subject. For example, A therapeutically effective amount of an ancestral virus or portion thereof is generally about 1×10 1 ~1×10 12 genome copies (GC) (e.g., about 1 × 10 3 ~1×10 9 GC) concentration The amount of the solution is in the range of about 0.1 ml to about 10 ml, containing the desired concentration. or expression is measured at various time points after administration by DNA, RNA or protein assays. In some instances, the expression level of the transgene can be monitored by The frequency and / or amount of the drug can be monitored to determine the therapeutic effect. A similar dosing regimen to that described for can be utilized for immunization.

[0065] The methods described herein also include one or more immunizations of a virus or a portion thereof. It can be used to model forward evolution to modify or remove endogenous domains. This can be done.

[0066] In accordance with the present invention, conventional molecular biology, microbiology, biochemistry and tissue engineering techniques within the skill of the art. Recombinant DNA techniques may be employed. Such techniques are fully explained in the literature. The invention is not limited in scope to the methods and compositions of interest, which are set forth in the appended claims. This is further illustrated in the following non-limiting examples. Working Example EXAMPLES

[0067] Computational prediction of ancestral sequences A set of 75 distinct amino acid sequences of the AAV capsid is available from numerous databases, including GenBank. The sequences were obtained from a number of public databases, and the sequences were analyzed using the PRANK-MSA algorithm. The file is aligned using option 121002 and option "-F".

[0068] ProtTest3 (e.g., Darriba et al., 2011, Bioinformatics, 27(8):1164-5 ;available on the World Wide Web at darwin.uvigo.es / software / prottest3) ,Under various conditions (e.g., those included in ProTest3, i.e., “+I”, “+ F”, “+G”, and combinations thereof) to various models of polypeptide evolution (e.g., P roTest3 includes JTT, LG, WAG, VT, CpRev, RtRev, Dayhoff, DCMut, FLU, Blosum62, VT, HIVb , MtArt, MtMam) were used to evaluate +G and +F (Yang, 1993 , Mol. Biol. Evol., 10:1396-1401; and Caoet al., 1994, J. Mol. Evol., 39:519-2 7) is used in the JTT model (Jones et al., 1992, Comp. Appl. Biosci., 8:275-82), The Akaike Information Criterion (AIC; Hirotugu, 1974, IE The selection was based on the results of the EE Transactions on Automatic Control, 19:716-23.

[0069] The phylogeny of AAV evolution was analyzed using PhyML (Guindon and Gascuel, 2003, Systematic Biolog The phylogenetic tree was constructed using the JTT+F substitution model (see Figure 3). The model was constructed using the ensemble model and had four discrete permutation categories and an estimated gamma shape parameter. The resulting phylogenetic tree was analyzed using Nearest Neighbor Interchange (NNI) and subtree division. -Improved through Subtree Pruning and Re-Grafting (SPR) Using the “SH-like” variant, bootstrap and approximate likelihood ratio tests (aLRT; (Anisimova and Gascuel, 2006, Systematic Biology, 55:539-52) It was evaluated as such.

[0070] Next, the phylogenetic tree constructed above shows that the AAV capsid ancestor is located at every node within the phylogenetic tree. The ancestral capsid sequence was used to estimate the state of Lazarus (sf.ne The Maximum Likelihood Phylogenetic Analysis (PAML) software included in Sourceforge software (Yang, 1997, Comp. Applic. BioSci., 13:555-6; a The maximum likelihood principle via More specifically, the Lazarus / PAML reconstruction was performed using 4 gamma-second It was set up to generate amino acid reconstructions with the JTT+F substitution model using cloth categories. AAV5 was used as the outgroup. Finally, the "I" option represents the PAML reconstruction. After this was done, indels were added to place the sequence (i.e., the Fitch algorithm were binary coded and arranged via maximum parsimony using

[0071] The reconstruction was done using a maximum likelihood method, so that any residue was chosen based on the likelihood that it was at a given position at a given node. To do this, an additional script is used to calculate the was written to identify all positions along the sequence that have a posterior probability of 0.3. A threshold is chosen such that any amino acid with a calculated posterior probability greater than 0.3 is These residues are the target residues in the library. It was selected to be a variant that:

[0072] To determine the sequence, additional utility must be coded for in selecting codons. The script was generated using another AAV sequence (the ANC80 scaffold sequence and approximately 92% of the sequence The codons with the same identity as AAVRh10 were derived and added to the codon substitution matrix. A novel algorithm for codon replacement in the event of sequence mismatches based on The novel algorithm is as follows: Given an amino acid sequence, Pt, with a corresponding nucleotide sequence, Nt, in this case N t encodes Pt; and the protein sequence, Pi, where Pi is highly homologous to Pt. Indicates gender. Needleman-Wunsch using Blosum62 table for scoring Align Pi and Pt by using the corresponding codons from Nt. By stepping on the annotation, a new nucleotide sequence, Ni, is generated. In this case, the amino acids in Pt match exactly to Pi, Codon-PAM matrix (Schneider et al., 2005, BMC Bioinform., 6:134) The "best scoring" codon from, where a substitution is present, A gap exists in Pi aligned to an amino acid in Pt. exists, and The most frequently occurring nucleotide in Nt (encoding a given amino acid), If, then there is an amino acid in Pi that is aligned against a gap in Pt.

[0073] In addition, two single nucleotide changes were identified in the AAV capsid gene in wild-type AAV. Transcription of assembly activating proteins (AAPs) encoded out of frame in the offspring The AAP (contemporary or ancestral) coding was used in this reconstruction. Therefore, expression of AAP was suppressed by making synonymous mutations in the cap sequence. The AAP sequence was removed by ligation and the AAP sequence was provided in trans during virus production. EXAMPLES

[0074] Expression of ancestral AAV VP1 sequences The experiments demonstrated that the predicted ancestral AAV capsid sequence can be used to generate viral vectors. This study was conducted to determine whether the method could be used to

[0075] A number of predicted ancestral AAV capsid sequences were cloned. The library was designed to allow the formation of viral particles in transient transfection. The rep-cap expression plasmid was used to express VP1 and VP2. To maintain splicing of VP2 and VP3, the library cap gene was The HindIII site located 5' of cap in the p coding sequence and the cap termination codon and Cloning was performed by cleaving the engineered SpeI fragment between the re-adenylation signals. As a result, the ancestral capsid was cloned into a more conventional "REP / CAP" construct. To clone the plasmid, digest it with HindIII and SpeI and gel purify it. and ligated into a similarly digested rep / cap plasmid.

[0076] The expressed polypeptides were separated on a 10% SDS gel. The capsid polypeptide was expressed properly and expressed multiple ancestral AAV sequences (Anc80L44, A nc80L27 and Anc80L65) and the contemporary AAV sequences AAV2 / 8 It is then spliced ​​into VP1, VP2, and VP3. EXAMPLES

[0077] Viral titer AAV contains a plasmid that encodes all the elements required for viral particle assembly. The antibody was produced in HEK293 cells via transient co-transfection of smids. To investigate this, HEK293 cells were grown to 90% confluence and transfected with (a) AAV2 A luciferase transgene flanked by ITRs (expressed by the CMV promoter) (b) a viral genome plasmid encoding AAV2 rep and the vectors disclosed herein; AAV packaging plus encoding the synthesized capsid proteins shown (c) AAV2-AAP expressing capsid, and (d) AAV packaging Transfect with adenovirus helper genes required for transcription and assembly The cells were incubated at 37° C. for 2 days, and the cells and medium were harvested and collected.

[0078] The cell-medium suspension was lysed by three successive freeze-thaw cycles. The lysate was then The mixture was clarified by centrifugation and incubated with an enzyme, here Benzyl phosphate buffer, under conditions that result in extensive DNA digestion. Treat with Onase™ to digest any DNA present on the outside of the viral particle The AAV preparations were compared to a control DNA template, in this case the vector genome. , of a linearized plasmid containing the same TaqMan™ primer and probe binding sequence. The PCR products were diluted to be within the linear measurement range. This was done using primers and probes that anneal to the virus vector genome. As shown in Table 2, the Ta in genome copies (GC) per milliliter (ml) Titers were calculated based on qMan™ measurements.

[0079] [Table 2]

[0080] Small-scale vector generation by ancestrally reconstituted AAV capsid particles results in AAV 2, but demonstrated reduced yields relative to AAV8, both of which are contemporary AA A vector preparation based on V. EXAMPLES

[0081] In vitro viral transduction In vitro viral transduction of AAV vectors containing predicted ancestral AAV sequences infects cells This was done to evaluate the ability of the virus to

[0082] After high-throughput vector generation using the sequenced Anc80 library, HEK2 93 cells were transduced with each viral vector. In addition to the Anc80 sequence, Each viral vector contained a luciferase transgene. Luciferin substrate was added to the transfected cells or cell lysates, and then the cells were incubated with a 96-well plate reader. After quantification, four linked 96-well plates were A heat map of luciferase expression in the plates was generated (pairwise in each plate). (Excluding the reference columns). The majority of inserts, Due to deletions and transitions, many of the vectors were non-functional. In addition, we transduced HEK293 cells with Only viruses (capable of expressing the transgene) were further evaluated.

[0083] HEK293 cells were transfected with two contemporary AAV vectors (AAV2 / 2 and AAV2 / 8) and three predicted ancestral AAV vectors (Anc80L27, Anc80L44 and and Anc80L65) at 1 × 10 cells 4 Equal genome copies (GC) Each vector contained a luciferase-encoding derivative. The cells contained either a transgene encoding the GFP or a transgene encoding eGFP. After 1 h, the cells were imaged using the GFP channel of an AMG EvosFl light microscope. Luciferase expression after in vitro transduction is shown. Each of the ancestral AAV viruses is Efficient transduction of EK293 cells was demonstrated. EXAMPLES

[0084] Retinal transduction in vivo Retinal transduction targets mouse retinal cells in vivo with ancestral AAV vectors This was done to determine whether it could be done.

[0085] Mouse eyes are 2 x 10 8 Three different ancestral AAVs (An c80L27, Anc80L44 and Anc80L65) and contemporary AAVs (AAV2 / 8), all of which contained a transgene encoding eGFP. For transduction, each AAV vector was administered via delivery of a vector bolus using an injection device. and surgically delivering it subretinally by creating a space between the photoreceptors and the retinal pigment epithelium layer. The vector bolus remained in the subretinal space, and the sub-subretinal detachment resolved over time. GFP expression was observed in the retina of animals after pupil dilation with Tropicamide™. The retinas were monitored non-invasively by fundus photography. All of the retinas shown were ancestral AAV demonstrated varying degrees of successful targeting of

[0086] Additionally, retinal histology was performed and visualized under a fluorescent microscope to identify the transduced cell type. Histology was performed on mice transduced with the Anc80L65 ancestral AAV vector described above. Anc80L65-mediated eGFP expression was localized in the outer nuclear layer (ONL), It is evident in the inner segment (IS) and retinal pigment epithelium (RPE), and is the ancestral An We demonstrated that the c80L65 vector targets mouse photoreceptor and retinal pigment epithelial cells. EXAMPLES

[0087] Neutralizing antibody assay Neutralizing antibody assays demonstrated that ancestral AAV viruses were more easily neutralized by antibodies than contemporary AAV viruses. Neutralizing antibody assays were performed to assess whether the antibody was more resistant to The antibody concentration (or experimental concentration) that neutralizes infection by 50% or more compared to a control in the absence of The antibody concentration (titer) of the sample is measured.

[0088] Serum samples or IVIG stock solution (200 mg / ml) were serially diluted two-fold and The undiluted and diluted samples were 4 Incubate the ancestral AAV vector at an MOI of 100 for approximately 30 min at 37 °C. The virus, Anc80L65, and the contemporary AAV virus, AAV2 / 8, were co-infected with Each virus contained a luciferase transgene. The antibody samples were transfected into HEK293 cells. The antibody samples collected were intravenous immunoglobulin (IVIG), blood samples from over 1000 blood donors. IgG extracted from plasma and pooled (e.g., Gammagard™ (Baxter er Healthcare; Deerfield, IL) or Gamnex™ (commercially available as Grifols; Los Angeles, Calif.). 48 hours after the start of transduction, cells were transfected by bioluminescence to detect luciferase. Neutralizing antibody titers were determined as ≥50% neutralization (transduction of sample / absence of sample). The dilution of the sample at which the transduction of the control virus was reached was determined by identifying the dilution of the sample at which the transduction of the control virus was reached. Ta.

[0089] As shown in Figure 8, significantly higher concentrations of IVIG were associated with the same phenotype as the contemporary AAV virus, AA Compared with V2 / 8, less than 50% of the no IVIG controls (dotted line) had ancestral AAV viruses These results suggest that the transduction efficiency of Anc80L65 is reduced by the addition of the α-terminal β-actin. showed that ancestral AAV viruses were more susceptible to neutralization by IVIG compared with contemporary AAV viruses. It shows higher resistance to EXAMPLES

[0090] Characterization of Anc80 Based on the methods described herein, the most likely Anc80 sequence (by posterior probability) (determined by the method described above) was obtained, and Anc80L1 (SEQ ID NO: 35 is the Anc80L1 capsid) was obtained. SEQ ID NO: 35 shows the nucleic acid sequence of the Anc80L1 VP1 polypeptide, and SEQ ID NO: 36 shows the amino acid sequence of the Anc80L1 VP1 polypeptide. The Anc80 probability library was provided by a commercial company and is designated herein as The sequences described were synthesized and subcloned into an expression vector.

[0091] The Anc80 library was assayed for vector yield and infectivity. Among these screening, Anc80L65 (SEQ ID NO:2) was 3), and several other mutants were further characterized.

[0092] The Anc80 library and Anc80L65 were compared in terms of sequence divergence ( Fig. 9 ; (The numbers above the diagonal indicate % and the numbers below indicate the number of amino acid differences.) The closest publicly available sequence to 0L65 is rh10 (GenBank accession no. AAO8 8201.1).

[0093] FIG. 10 shows that Anc80L65 produced vector yields comparable to AAV2 (panel (Panel A), and produced virus particles under transmission electron microscopy (TEM) (Panel B). AAV cap and VP1, 2, and 3 proteins based on SDS page under anaerobic conditions (Panel C) and the AAV capsid antibody, B1, were used to A Western blot (Panel D) is shown. These experiments are described in more detail in the following paragraphs. can be.

[0094] Briefly, AAV2 / 8, AAV2 / 2, AAV2 / Anc80L27, AAV2 / A The nc80L44 and AAV2 / Anc80L65 vectors express a gene encoding a receptor consisting of eGFP. A small-scale expression vector was generated containing the transporter construct, which was then driven by the CMV promoter. The ferase was produced on a small scale. The titers of these small scale preparations of virus were then , obtained via quantitative PCR. Based on these experiments, Anc80L27, Anc8 0L44 and Anc80L65 vectors generate virus levels comparable to AAV2 It was found that the α-terminal region of the nucleus was increased by 100% (Fig. 10A

[0095] The Anc80L65 capsid protein assembles the complete virus into the correct size and conformation. To confirm that the nucleosomes are assembled into luciferase-like particles, transmission electron microscopy (TEM) was used. A large-scale purified preparation of Anc80-L065 was obtained using poly(Asp-1, β-lactam). Vinyl formal (Formvar®) coated copper grids were then loaded with Stained with uranyl acetate, the micrographs show intact hexagonal granules with diameters of 20–25 nm. particles were shown (Figure 10B).

[0096] Was the synthetic ancestral capsid gene processed (i.e., spliced ​​and expressed) normally? To determine whether AAV2 / 8, AAV2 / 2, and AAV2 / Anc80L6 Large-scale, purified preparations of the 5 vectors were loaded onto SDS-PAGE gels under denaturing conditions (1E10 GC / well). Viral capsid proteins VP1, VP2 and VP A band representing AAV capsid 3 was clearly present in each vector preparation (Fig. 10C). Western blot analysis using the cytochrome P450 antibody B1 further confirmed these predicted bands. It was confirmed that the protein was expressed (Figure 10D).

[0097] Furthermore, FIG. 11 shows that Anc80L65 inhibits the readout (panel A) or luciferase (Panel B) vs. AAV2 and / or AAV8, with GFP as a control, at MOI 10E4 GC / cell in HEK293 cells in vitro in mammalian tissues and cells In addition, Anc80L65 was infected with the nuclear LacZ transgene. After IV injection of the indicated AAV encoding GFP (top row, panel C), After direct intramuscular (IM) injection of AAV (middle row, panel C) and GFP-coated Following subretinal injection with the indicated AAV (bottom row, panel C), the liver was effectively targeted. These experiments are described in more detail in the following paragraphs.

[0098] To obtain a relative measure of the infectivity of ancestral virions, we expressed eG under the control of the CMV promoter. A containing a bicistronic receptor construct containing the FP sequence and the firefly luciferase sequence AV2 / 2, AAV2 / 8, AAV2 / Anc80L65, AAV2 / Anc80L44 , AAV2 / Anc80L27, AAV2 / Anc80L121, AAV2 / Anc80 L122, AAV2 / Anc80L123, AAV2 / Anc80L124, and AAV 2 / Anc80L125 was generated. The well plates were cultured at an MOI of 1E4 GC / cell (as determined by qPCR as described above). After 48 hours, the cells were subjected to transduction with each vector at 100 μg / ml (titer). The presence of GRP in the transfected cells was confirmed (Figure 11A). (FIG. 11B), which was assayed for the presence of Luciferase expression in transduced cells was significantly higher in AAV8 (low level of transduction) and AAV 2 (high level of transduction).

[0099] To assess the relative efficiency of gene transfer in an in vivo context, AAV2 / 2 Thus, purified, high-titer preparations of AAV2 / 8 and AAV2 / Anc80L65 were obtained. 3.9E10 GC vectors encode nuclear LacZ under the control of the TBG promoter. The transgene was then injected IP into C57BL / 6 mice (Fig. Mice were sacrificed 28 days after injection and tissues were harvested. The organs were sectioned by standard histological techniques and stained for β-galactosidase. Sections were then imaged under a microscope, and representative images are shown in the top row of Figure 11C.

[0100] Subsequently, two vectors encoding eGFP and hA1AT under the control of the pCASI promoter were inserted. Vectors of the same serotype containing cistronic transgenes were obtained. To evaluate the ability of Anc80L65 to be introduced, each vector in 1E10GC was After partial anesthesia, C57BL / 6 mice (five mice per condition) were injected into the skeletal muscle. Twenty-eight days after injection, mice were sacrificed, tissues were cryosectioned, and the presence of eGFP was examined by fluorescence confocal microscopy. The cells were evaluated using a microscope (blue is DAPI and green is eGFP). Representative images These experiments are shown in the middle row of Figure 11C. demonstrated that the skeletal muscle of mice could be transduced with

[0101] Here, we created a construct encoding only the eGFP transgene under the control of the CMV promoter. The capsid-forming vector of the same serotype was obtained. 2E9 particles were C57BL / 6 mice were injected subretinal. 28 days after injection, the mice were sacrificed and the eyes were rotated. Cells were harvested, cryosectioned, and assessed for the presence of eGFP using fluorescent confocal microscopy (blue indicates (Green is DAPI, green is eGFP.) Representative images are shown in the bottom row of FIG. 11C. These experiments demonstrated that the Anc80L65 vector can express markers at levels comparable to those of the AAV8 vector. We demonstrate that mouse retina can be transduced with IgG1.

[0102] Figure 12 shows the seroprevalence of ancestral viral vectors compared with current AAV viral vectors. The results of experiments evaluating Anc80 using an in vitro neutralizing antibody assay are shown. L65 has been shown to exhibit increased resistance to neutralization with IVIG, , which is a pooled serum sample of approximately 10,000 individuals (Figure 12A). Blood from individuals in Ghee (n=100; Fig. S12C) or Boston (n=102; Fig. S12B) The results are box plots versus AAV2,8, and similar seroprevalence versus rh32.33, i.e. i.e., it has minimal known seroprevalence but is of limited use as a gene therapy vector Reduced susceptibility (or resistance) to neutralization of Anc80L65 in different AAV vectors Sera obtained from cynomolgus monkeys demonstrated a similar increase in resistance vs. A We demonstrated that AV2,8 and rh32.33 are involved in the expression of rh32.33 (Figure 12D). These experiments are summarized in the following paragraphs. It will be described in more detail.

[0103] Briefly, a plasmid containing eGFP and firefly luciferase under the control of a CMV promoter was generated. AAV2 / 8, AAV2 / 2, and AAV2 encapsidating cistronic transgenes Purified high titer of / rh32.33 and AAV2 / Anc80L65 viral vectors These vectors were then diluted in 2-fold serial dilutions of IVIG (10 mg, 5 mg, 2.5 mg, etc.) or without IVIG (per condition) After incubation, the vector was used to transfect the HEK293 cells were transduced at an MOI of 1E4 per well (1 dilution per well). After 48 hours, the relative amount of luciferase was assayed by luminescence assay. Transduction of 100% β-lactam sera from 100% β-lactam sera is shown in Figure 12A. A similar experiment was performed in Belgium (n=100; Figure 1 2C) or Boston (n=102; Fig. 12B). For serum samples, neutralization titers were calculated as a 50% reduction in a given vector relative to the no serum control. Neutralization titers are reported as dilutions at 100°C and 100°C, respectively, as box and whisker plots in Figures 12B and 12C. reported that the Anc80L65 vector is more effective than AAV2 and AAV8 in the human population. , less positive rates in both Belgium and Boston, which is due to Rh32. This is approaching the level of 33 (a different AAV vector with the lowest known seroprevalence). Serum obtained from macaques was assayed in a similar manner (FIG. 12D), where AAV2 However, the seroprevalence was significantly lower compared to AAV8 and Rh32.33 vectors. It was found that: EXAMPLES

[0104] Production of additional ancestral AAV capsids The most likely ancestral AAV capsid sequence (determined by posterior probability) is then It was synthesized via a commercial laboratory (Gen9) and provided as linear dsDNA. These amino acid sequences were compared with extant AAV sequences to determine the extent to which they differ. The ancestral VP1 proteins were selected at 3.6% to 9.3% of the total genomes (Fig. 13). The VP3 protein of the ancestral AAV is different from that of the representative extant AAV (Fig. 13A). The difference is 4.2 to 9.4% (Figure 13B). These capsids are AAV production via digestion (HindIII & SpeI) and T4 ligation plus These clones were then subcloned into pAA vector 2 / empty. Generate mid-scale preparations of plasmid DNA and then confirm by Sanger sequencing did.

[0105] Each of these plasmids was then transformed into a vector encoding both eGFP and firefly luciferase. The AAV vectors were used to generate reporter genes that correspond to the These vectors were generated in triplicate on a small scale, as described above. Crude virus preparations were then quantified. Titered via PCR, viral particles were 2.71% to 183.1% lower than AAV8. These titers were then used to A titer control experiment was set up to evaluate the infectivity of Anc126. The titer was not controlled because the infection was reduced. The infectivity of other viruses in this study cannot be accurately compared. Transfect HEK293 cells at a multiplicity of infection (MOI) of 1.9E3 GC / cell using a . Transduced.

[0106] Sixty hours after transduction, cells were assessed for GFP expression by fluorescence microscopy. eGFP-positive cells were detected under each condition except for the negative control (Figure 16). Each of the predicted, synthesized and cloned ancestral sequences produced a viable infectious virus. To get an idea of ​​the relative levels of infectivity, Next, luciferase assay was also performed on the same cells. The results showed that the ancestral vector Each of these transduced HEK293 cells 28.3% to 850.8% more efficiently than AAV8. This shows that it is possible to achieve this (Figures 17 and 18). Note that Anc126 was excluded from the analysis of relative transduction.

[0107] In summary, eight novel ancestral AAV capsid genes have been synthesized, designated AAV8, AA Used together with V2 and the previously described Anc80L65 vector to generate functional viral vectors Production and infectivity were assessed in vitro and findings are summarized in Figure 19. . EXAMPLES

[0108] Vector immunoprophylaxis In vectored immunoprophylaxis, gene therapy vehicles (such as AAV) are used to protect against infectious agents. For example, Balazs et al. (2013, Nat. Biotechnol., 31:647-52); Limberis et al. (2013, Sci Transl. Med., 5:187ra72); Balazs et al. (2012, Nature, 481:81-4); and De See al et al. (2014, PNAS USA, 111:12528-32). One advantage of this treatment is The host produces antibodies in its own cells, which means that a single administration of the pathogen This means that it has the potential to confer a lifetime of protection against EXAMPLES

[0109] Drug Delivery Vehicle LUCENTIS® (ranibizumab) and AVASTIN® ( bevacizumab) and vascular endothelial growth factor A (VEGF-A) are both expressed against the same humanized mouse It is an antiangiogenic agent based on a monoclonal antibody. Bevacizumab is a full-length antibody and is Both of them act by antagonizing VEGF. It acts through the same mechanism to treat wet age-related macular degeneration. et al.(2011, Hum. Gene Ther., 22:1525-35); Xie et al.(2014, Gynecol. Oncol., doi: 10.1016 / j.ygyno.2014.07.105); and Watanabe et al. (2010, Gene Ther., 1 7:1042-51. Because both of these molecules are proteins, they are not related to DNA. and produced in cells transduced with a vector containing a transgene encoded by and is small enough to be packaged into an AAV vector.

[0110] Other Aspects The subject methods and compositions are described herein in conjunction with a number of different embodiments, including, but not limited to, The foregoing description of certain embodiments is intended to be illustrative and to expand the scope of the subject methods and compositions. It should be understood that the present invention is not limited to the disclosed subject matter. Other aspects, advantages, and modifications are set forth in the following claims. It is within the range.

[0111] may be used in or in combination with the disclosed methods and compositions; Methods and compositions that can be used in the preparation of, or are the product of, these are disclosed. The substances and other substances disclosed herein are intended to be included in the methods and compositions of the present invention. It is understood that sets, interactions, groups, etc. are disclosed. Specific reference to combinations and aggregates and permutations of these compositions is expressly incorporated herein by reference. Although not all are listed, each is specifically contemplated and described herein. For example, a particular composition or method of interest may be disclosed and discussed, and numerous compositions may be used. When an article or method is discussed, each and every combination of the composition and method is included. Permutations are specifically contemplated unless specifically stated to the contrary. Any subset or combination is also specifically contemplated and disclosed.

[0112] Appendix A SEQ ID NO:1: Anc80 polypeptide

[0113] [ka]

[0114] SEQ ID NO:2: Anc80 DNA

[0115] [ka]

[0116] SEQ ID NO:3: Anc81 polypeptide

[0117] [ka]

[0118] SEQ ID NO: 4: Anc81 DNA

[0119] [ka]

[0120] SEQ ID NO:5: Anc82 polypeptide

[0121] [ka]

[0122] SEQ ID NO: 6: Anc82 DNA

[0123] [ka]

[0124] SEQ ID NO: 7: Anc83 polypeptide

[0125] [ka]

[0126] SEQ ID NO: 8: Anc83 DNA

[0127] [ka]

[0128] SEQ ID NO: 9: Anc84 polypeptide

[0129] [ka]

[0130] SEQ ID NO: 10: Anc84 DNA

[0131] [ka]

[0132] SEQ ID NO: 11: Anc94 polypeptide

[0133] [ka]

[0134] SEQ ID NO: 12: Anc94 DNA

[0135] [ka]

[0136] SEQ ID NO: 13: Anc113 polypeptide

[0137] [ka]

[0138] SEQ ID NO: 14: Anc113 DNA

[0139] [ka]

[0140] SEQ ID NO: 15: Anc126 polypeptide

[0141] [ka]

[0142] SEQ ID NO: 16: Anc126 DNA

[0143] [ka]

[0144] SEQ ID NO: 17: Anc127 polypeptide

[0145] [ka]

[0146] SEQ ID NO: 18: Anc127 DNA

[0147] [ka]

[0148] SEQ ID NO:19: L0027 Polypeptide

[0149] [ka]

[0150] SEQ ID NO:20: L0059 Polypeptide

[0151] [ka]

[0152] SEQ ID NO:21: L0060 Polypeptide

[0153] [ka]

[0154] SEQ ID NO:22: L0062 Polypeptide

[0155] [ka]

[0156] SEQ ID NO:23: L0065 Polypeptide

[0157] [ka]

[0158] SEQ ID NO:24: L0033 Polypeptide

[0159] [ka]

[0160] SEQ ID NO:25: L0036 Polypeptide

[0161] [ka]

[0162] SEQ ID NO:26: L0044 Polypeptide

[0163] [ka]

[0164] SEQ ID NO:27: AAV8 VP1 polypeptide

[0165] SEQ ID NO:28: AAV9 VP1 polypeptide

[0166] SEQ ID NO:29: AAV6 VP1 polypeptide

[0167] SEQ ID NO:30: AAV1 VP1 polypeptide

[0168] SEQ ID NO:31: AAV2 VP1 polypeptide

[0169] SEQ ID NO:32: AAV3 VP1 polypeptide

[0170] SEQ ID NO:33: AAV3B VP1 polypeptide

[0171] SEQ ID NO:34: AAV7 VP1 polypeptide

Claims

1. An adeno-associated virus (AAV) capsid polypeptide having the amino acid sequence shown in SEQ ID NO:

5.

2. A purified AAV capsid polypeptide described in claim 1.

3. An AAV capsid polypeptide described in claim 1, encoded by the nucleic acid sequence shown in SEQ ID NO:

6.

4. A nucleic acid molecule encoding an adeno-associated virus (AAV) capsid polypeptide having the nucleic acid sequence shown in SEQ ID NO:

6.

5. A vector comprising the nucleic acid molecule described in claim 4.

6. A host cell containing the vector described in claim 5.

7. A purified viral particle comprising an AAV capsid polypeptide according to any one of claims 1 to 3.

8. A purified viral particle as described in claim 7, further comprising an introduced gene.

9. A composition for gene transfer and / or vaccination using an introduced gene, comprising the viral particle of claim 8.

10. A vaccine comprising a coding sequence for a target antigen encapsulated in the AAV capsid polypeptide described in claim 1.

Citation Information

Patent Citations

  • Ancestral viruses and vaccines

    JP2007500518A

  • Adeno-associated virus (aav) homologous phylogenies, sequences, vectors containing them and uses thereof

    JP2007507223A